(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 3 837 274 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
06.11.2024 Bulletin 2024/45

(21) Application number: **19850610.7**

(22) Date of filing: **05.08.2019**

(51) International Patent Classification (IPC):
C12N 15/113 *(2010.01)* ***C07K 14/00*** *(2006.01)*
A61P 17/00 *(2006.01)* ***A61Q 19/08*** *(2006.01)*

(52) Cooperative Patent Classification (CPC):
C12N 9/93; A61K 8/64; A61K 38/53; A61P 17/00; A61Q 19/08; C12N 15/1137; C12Y 604/01002; A61K 38/00; C12N 2310/11; C12N 2310/3181

(86) International application number:
PCT/KR2019/009697

(87) International publication number:
WO 2020/036353 (20.02.2020 Gazette 2020/08)

(54) ACETYL-COA CARBOXYLASE2 ANTISENSE OLIGONUCLEOTIDES

ACETYL-COA-CARBOXYLASE2-ANTISENSE-OLIGONUKLEOTIDE

OLIGONUCLÉOTIDES ANTISENS ACÉTYL-COA CARBOXYLASE2

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **14.08.2018 KR 20180095124**

(43) Date of publication of application:
23.06.2021 Bulletin 2021/25

(73) Proprietor: **Olipass Corporation**
Yongin-si, Gyeonggi-do 17015 (KR)

(72) Inventors:
- **HAN, Seon-Young**
  Chuncheon-si, Gangwon-do 24336 (KR)
- **SUNG, Kiho**
  Yongin-si, Gyeonggi-do 17045 (KR)
- **HONG, Myunghyo**
  Suwon-si, Gyeonggi-do 16247 (KR)
- **KANG, Dayoung**
  Seoul 04426 (KR)
- **HEO, Jeong-Seok**
  Yongin-si, Gyeonggi-do 17013 (KR)
- **JANG, Kang Won**
  Yongin-si, Gyeonggi-do 16998 (KR)

(74) Representative: **Schlich**
9 St Catherine's Road
Littlehampton
West Sussex BN17 5HS (GB)

(56) References cited:
WO-A1-2018/029517
WO-A1-2018/122610
WO-A1-2018/127733
WO-A2-2006/110775
WO-A2-2006/110775
KR-A- 20120 073 536
US-A1- 2017 340 544

- **YUCESOY BERRAN ET AL: "Genetic Basis of Irritant Susceptibility in Health Care Workers", JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE., vol. 58, no. 8, August 2016 (2016-08-01), US, pages 753 - 759, XP055902132, ISSN: 1076-2752, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Yerkebulan-Talzhanov/publication/303373527_Genetic_Basis_of_Irritant_Susceptibility_in_Health_Care_Workers/links/5d1f072da6fdcc2462c10f50/Genetic-Basis-of-Irritant-Susceptibility-in-Health-Care-Workers.pdf> DOI: 10.1097/JOM.0000000000000784**

Processed by Luminess, 75001 PARIS (FR)

(Cont. next page)

- **SAVAGE DAVID B ET AL: "Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2", THE JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 116, no. 3, 1 March 2006 (2006-03-01), pages 817 - 824, XP008137550, ISSN: 0021-9738, DOI: 10.1172/JCI27300**
- **LEE JUNG-KEE ET AL: "Roles of Acetyl-CoA Carboxylase [beta] in Muscle Cell Differentiation and in Mitochondrial Fatty Acid Oxidation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 254, no. 3, 27 January 1999 (1999-01-27), Amsterdam NL, pages 657 - 660, XP055902015, ISSN: 0006-291X, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0006291X98901139/pdf?md5=47bc229b0f3da3c61a11427136fbb4ab&pid=1-s2.0-S0006291X98901139-main.pdf> DOI: 10.1006/bbrc.1998.0113**
- **WAKIL SALIH J. ET AL: "Fatty acid metabolism: target for metabolic syndrome", JOURNAL OF LIPID RESEARCH, vol. 50, 1 December 2008 (2008-12-01), US, pages S138 - S143, XP055902052, ISSN: 0022-2275, DOI: 10.1194/jlr.R800079-JLR200**
- **HARRIS IAN R. ET AL: "Permeability Barrier Disruption Coordinately Regulates mRNA Levels for Key Enzymes of Cholesterol, Fatty Acid, and Ceramide Synthesis in the Epidermis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 109, no. 6, December 1997 (1997-12-01), NL, pages 783 - 787, XP055902155, ISSN: 0022-202X, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/271007/1-s2.0-S0022202X97X96009/1-s2.0-S0022202X15430684/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBYaCXVzLWVhc3QtMSJIMEYCIQDZHUPjoskkgRhvqNyPFkYBon1U2fnCINDaFcv7lSQhCwIhAMaaxT+8Tp9Fx0Vt05dmxKTOnv1mIvcvNKfDhmDu3coeKoMECI//////////wEQBBoMMDU5MDAzNTQ2ODY1IgzUx> DOI: 10.1111/1523-1747.ep12340962**

Remarks:

The complete document including Reference Table(s) and the Sequence Listing(s) can be downloaded from the EPO website

Description

Technical Field

[0001] This invention relates to peptide nucleic acid derivatives complementarily targeting the human acetyl-CoA carboxylase2 pre-mRNA for improvement of skin aging mediated by acetyl-CoA carboxylase2.

Background Art

[0002] Skin aging has received considerable attention since the signs of aging are most visible in the skin. Skin aging begins in their middle or late twenties with the reduction of collagen and elastin in the skin to result in dry and low elastic skin and even wrinkles. Obesity is a kind of inflammation reaction caused by the decline in blood circulation came from excessively deposited internal fat. Internal fat on blood vessel inhibits blood circulation and secretion of various hormones to promote aging in the whole body including the skin. In that sense, health conditions and diseases linked to obesity have to be monitored to get healthy and beautiful skin.

[0003] The biosynthesis and degradation of fatty acids are well regulated according to the physiological conditions to meet the demand of the body. Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the carboxylation of acetyl-CoA to produce malonyl-CoA, which is the rate-determining step in the first stage of fatty acid biosynthesis.



[0004] ACC has a function of controlling metabolism of fatty acids in two ways. The most important function of ACC is to provide the malonyl-CoA substrate as a new building block in its active state for the fatty acid biosynthesis. Another function is to block the oxidation of fatty acids in mitochondria through inhibition of acyl group transfer of fatty acids.

[0005] In human, two main isoforms of ACC are expressed, acetyl-CoA carboxylase 1 (ACC1, ACACA, acetyl-CoA carboxylase alpha) and acetyl-CoA carboxylase 2 (ACC2, ACACB, acetyl-CoA carboxylase beta). Two ACCs have different functions each other, i.e., ACC1 maintains regulation of fatty acid synthesis whereas ACC2 mainly regulates fatty acid oxidation.

[0006] ACCs regulating biosynthesis and oxidation of fatty acids are potential targets for the treatment of many diseases such as new antibiotics utilizing the structure differences of bacteria and human ACCs, metabolic syndrome of diabetics and obesity, lipogenesis related growth inhibitors of cancer cell, and so on [Recent Patents Cardiovasc. Drug Discov. Vol 2, 162-80 (2007); PLoS One Vol 12, e0169566 (2017)].

[0007] Among them, a study on the $ACC2^{-/-}$ mutant mice has attracted lots of attention, where ACC2-deficient mice had lower level of fat with a higher fatty acid oxidation rate, lost or maintained body weight in spite of more food consumption, and had reduced risk of diabetes [Science Vol 291, 2613-6 (2001)]. These results suggested the possibility of ACC2 inhibitors to have a therapeutic effect on obesity and diabetes. In addition, treatment of the inhibitors to the skin may expect the effect of fat removal and eventually the prevention of obesity in the skin and the improvement of skin aging.

[0008] Considering the significance of obesity in skin aging process, it is very interesting and necessary to develop ACC2 inhibitors or the pharmaceuticals or cosmetics based on the mechanism of ACC2 expression, which may improve and prevent skin aging condition.

[0009] Pre-mRNA: Genetic information is carried on DNA (2-deoxyribose nucleic acid). DNA is transcribed to produce pre-mRNA (pre-messenger ribonucleic acid) in the nucleus. Mammalian pre-mRNA usually consists of exons and introns, and exon and intron are interconnected to each other as schematically provided below. Exons and introns are numbered as exemplified in the drawing below.



[0010] Splicing of Pre-mRNA: Pre-mRNA is processed into mRNA following deletion of introns by a series of complex reactions collectively called "splicing" which is schematically summarized in the diagram below [Ann. Rev. Biochem. 72(1), 291-336 (2003); Nature Rev. Mol. Cell Biol. 6(5), 386-398 (2005); Nature Rev. Mol. Cell Biol. 15(2), 108-121 (2014)].



[0011] Splicing is initiated by forming "spliceosome E complex" (i.e. early spliceosome complex) between pre-mRNA and splicing adapter factors. In "spliceosome E complex", U1 binds to the junction of exon N and intron N, and $U2AF^{35}$ binds to the junction of intron N and exon (N+1). Thus the junctions of exon/intron or intron/exon are critical to the formation of the early spliceosome complex. "Spliceosome E complex" evolves into "spliceosome A complex" upon additional complexation with U2. The "spliceosome A complex" undergoes a series of complex reactions to delete or splice out the intron to adjoin the neighboring exons.

[0012] Ribosomal Protein Synthesis: Proteins are encoded by DNA (2-deoxyribose nucleic acid). In response to cellular stimulation or spontaneously, DNA is transcribed to produce pre-mRNA (pre-messenger ribonucleic acid) in the nucleus. The introns of pre-mRNA are enzymatically spliced out to yield mRNA (messenger ribonucleic acid), which is then translocated into the cytoplasm. In the cytoplasm, a complex of translational machinery called ribosome binds to mRNA and carries out the protein synthesis as it scans the genetic information encoded along the mRNA [Biochemistry vol 41, 4503-4510 (2002); Cancer Res. vol 48, 2659-2668 (1988)].

[0013] Antisense Oligonucleotide (ASO): An oligonucleotide binding to nucleic acid including DNA, mRNA and pre-mRNA in a sequence specific manner (i.e. complementarily) is called antisense oligonucleotide (ASO).

[0014] If an ASO tightly binds to an mRNA in the cytoplasm, for example, the ASO may be able to inhibit the ribosomal protein synthesis along the mRNA. ASO needs to be present within the cytoplasm in order to inhibit the ribosomal protein synthesis of its target protein.

[0015] Antisense Inhibition of Splicing: If an ASO tightly binds to a pre-mRNA in the nucleus, the ASO may be able to inhibit or modulate the splicing of pre-mRNA into mRNA. ASO needs to be present within the nucleus in order to inhibit or modulate the splicing of pre-mRNA into mRNA. Such antisense inhibition of splicing produces an mRNA or mRNAs lacking the exon targeted by the ASO. Such mRNA(s) is called "splice variant(s)", and encodes protein(s) smaller than the protein encoded by the full-length mRNA.

[0016] In principle, splicing can be interrupted by inhibiting the formation of "spliceosome E complex". If an ASO tightly binds to a junction of (5' → 3') exon-intron, i.e. "5' splice site", the ASO blocks the complex formation between pre-mRNA and factor U1, and therefore the formation of "spliceosome E complex". Likewise, "spliceosome E complex" cannot be formed if an ASO tightly binds to a junction of (5' → 3') intron-exon, i.e. "3' splice site".

[0017] 3' splice site and 5' splice site are schematically illustrated in the drawing provided below.



[0018] Unnatural Oligonucleotides: DNA or RNA oligonucleotides are susceptible to degradation by endogenous nucleases, limiting their therapeutic utility. To date, many types of unnatural (naturally non-occurring) oligonucleotides have been developed and studied intensively [Clin. Exp. Pharmacol. Physiol. vol 33, 533-540 (2006)]. Some of them show extended metabolic stability compared to DNA and RNA. Provided below are the chemical structures for a few of representative unnatural oligonucleotides. Such oligonucleotides predictably bind to a complementary nucleic acid as DNA or RNA does.



B : Nucleobase

[0019] Phosphorothioate Oligonucleotide: Phosphorothioate oligonucleotide (PTO) is a DNA analog with one of the backbone phosphate oxygen atoms replaced with a sulfur atom per monomer. Such a small structural change made PTO comparatively resistant to degradation by nucleases [Ann. Rev. Biochem. vol 54, 367-402 (1985)].

[0020] Reflecting the structural similarity in the backbone of PTO and DNA, they both poorly penetrate the cell membrane in most mammalian cell types. For some types of cells abundantly expressing transporter(s) of DNA, however, DNA and PTO show good cell penetration. Systemically administered PTOs are known to readily distribute to the liver and kidney [Nucleic Acids Res. vol 25, 3290-3296 (1997)].

[0021] In order to facilitate PTO's cell penetration in vitro, lipofection has been popularly practiced. However, lipofection physically alters the cell membrane, causes cytotoxicity, and therefore would not be ideal for long term in vivo therapeutic use.

[0022] Over the past 30 years, antisense PTOs and variants of PTOs have been clinically evaluated to treat cancers, immunological disorders, metabolic diseases, and so on [Biochemistry vol 41, 4503-4510 (2002); Clin. Exp. Pharmacol. Physiol. vol 33, 533-540 (2006)]. Many of such antisense drug candidates have not been successfully developed partly due to PTO's poor cell penetration. In order to overcome the poor cell penetration, PTO needs to be administered at high dose for therapeutic activity. However, PTOs are known to be associated with dose-limiting toxicity including increased coagulation time, complement activation, tubular nephropathy, Kupffer cell activation, and immune stimulation including splenomegaly, lymphoid hyperplasia, mononuclear cell infiltration [Clin. Exp. Pharmacol. Physiol. vol 33, 533-540 (2006)].

[0023] Many antisense PTOs have been found to show due clinical activity for diseases with a significant contribution from the liver or kidney. Mipomersen is a PTO analog which inhibits the synthesis of apoB-100, a protein involved in LDL cholesterol transport. Mipomersen manifested due clinical activity in atherosclerosis patients most likely due to its preferential distribution to the liver [Circulation vol 118(7), 743-753 (2008)]. ISIS-113715 is a PTO antisense analog inhibiting the synthesis of protein tyrosine phosphatase 1B (PTP1B), and was found to show therapeutic activity in type II diabetes patients. [Curr. Opin. Mol. Ther. vol 6, 331-336 (2004)].

[0024] Locked Nucleic Acid: In locked nucleic acid (LNA), the backbone ribose ring of RNA is structurally constrained to increase the binding affinity for RNA or DNA. Thus, LNA may be regarded as a high affinity DNA or RNA analog [Biochemistry vol 45, 7347-7355 (2006)].

[0025] Phosphorodiamidate Morpholino Oligonucleotide: In phosphorodiamidate morpholino oligonucleotide (PMO), the backbone phosphate and 2-deoxyribose of DNA are replaced with phosphoramidate and morpholine, respectively [Appl. Microbiol. Biotechnol. vol 71, 575-586 (2006)]. Whilst the DNA backbone is negatively charged, the PMO backbone is not charged. Thus the binding between PMO and mRNA is free of electrostatic repulsion between the backbones, and tends to be stronger than that between DNA and mRNA. Since PMO is structurally very different from DNA, PMO wouldn't be recognized by the hepatic transporter recognizing DNA. PMO may exhibit a different tissue distribution than PTO, but PMO, like PTO, doesn't readily penetrate the cell membrane.

[0026] Peptide Nucleic Acid: Peptide nucleic acid (PNA) is a polypeptide with N-(2-aminoethyl)glycine as the unit backbone, and was discovered by Dr. Nielsen and colleagues [Science vol 254, 1497-1500 (1991)]. The chemical structure and abbreviated nomenclature of PNA are illustrated in the drawing provided below. Like DNA and RNA, PNA also selectively binds to complementary nucleic acid.. [Nature (London) vol 365, 566-568 (1992)]. In binding to complementary nucleic acid, the N-terminus of PNA is regarded as equivalent to the "5'-end" of DNA or RNA, and the C-terminus of PNA as equivalent to the "3'-end" of DNA or RNA.



[0027] Like PMO, the PNA backbone is not charged. Thus the binding between PNA and RNA tends to be stronger than the binding between DNA and RNA. Since PNA is markedly different from DNA in the chemical structure, PNA wouldn't be recognized by the hepatic transporter(s) recognizing DNA, and would show a tissue distribution profile

different from that of DNA or PTO. However, PNA also poorly penetrates the mammalian cell membrane [Adv. Drug Delivery Rev. vol 55, 267-280 (2003)].

[0028] Modified Nucleobases to Improve Membrane Permeability of PNA: PNA was made highly permeable to mammalian cell membrane by introducing modified nucleobases with a cationic lipid or its equivalent covalently attached thereto. The chemical structures of such modified nucleobases are provided below. Such modified nucleobases of cytosine, adenine, and guanine were found to predictably and complementarily hybridize with guanine, thymine, and cytosine, respectively [PCT Appl. No. PCT/KR2009/001256; EP2268607; US8680253].



[0029] Incorporation of such modified nucleobases onto PNA resembles situations of lipofection. By lipofection, oligonucleotide molecules with phosphate backbone are wrapped with cationic lipid molecules such as lipofectamine, and such lipofectamine/oligonucleotide complexes tend to penetrate membrane rather easily as compared to naked oligonucleotide molecules.

[0030] In addition to good membrane permeability, those PNA derivatives were found to possess ultra-strong affinity for complementary nucleic acid. For example, introduction of 4 to 5 modified nucleobases onto 11- to 13-mer PNA derivatives easily yielded a T_m gain of 20°C or higher in duplex formation with complementary DNA. Such PNA derivatives are highly sensitive to a single base mismatch. A single base mismatch resulted in a T_m loss of 11 to 22°C depending on the type of modified base as well as PNA sequence.

[0031] Small Interfering RNA (siRNA): Small interfering RNA (siRNA) refers to a double stranded RNA of 20-25 base pairs [Microbiol. Mol. Biol. Rev. vol 67(4), 657-685 (2003)]. The antisense strand of siRNA somehow interacts with proteins to form an "RNA-induced Silencing Complex" (RISC). Then the RISC binds to a certain portion of mRNA complementary to the antisense strand of siRNA. The mRNA complexed with the RISC undergoes cleavage. Thus siRNA catalytically induces the cleavage of its target mRNA, and consequently inhibits the protein expression by the mRNA. The RISC does not always bind to the full complementary sequence within its target mRNA, which raises concerns relating to off-target effects of an siRNA therapy. Like other classes of oligonucleotide with DNA or RNA backbone, siRNA possesses poor cell permeability and therefore tends to show poor in vitro or in vivo therapeutic activity unless properly formulated or chemically modified to have good membrane permeability.

[0032] ACC siRNA: The mixture of ACC1 siRNA and ACC2 siRNA was reported to inhibit the expression of ACC1 and ACC2 mRNAs and proteins in glioblastoma cancer cell line following a lipofection at 20 nM each [PLoS One Vol 12, e0169566 (2017)]. These results may be useful to the study of ACC related lipogenic cancer metastasis.

[0033] WO2007/110775, in the name of Isis Pharmaceutical Inc. describes antisense oligonucleotides that are complementary to part of the ACC2 pre-mRNA and which may be synthesized as peptide nuclide acids. These target certain part of the human ACC2 pre-mRNA. The document refers to the possibility of perturbing splice site selection, but the majority of the specific antisense oligonucleotides taught in this document are gapmers. WO2018/122610, in the name of Olipas Corp, describes the design of peptide nucleic acids comprising the nucleobase analogues of Formulae II, III and IV. Neither document suggests the design of antisense oligonucleotides targeting the exon 12/intron 12 junction of the human ACC2 pre-mRNA.

Disclosure of the Invention

Problem to be solved

[0034] Since obesity has a profound effect on skin aging, health conditions and diseases linked to obesity have to be monitored to get healthy and beautiful skin.

[0035] A study on the ACC2-/- mutant mice with respect to obesity has attracted lots of attention. In addition, although ACCs siRNA were reported to inhibit the expression of ACCs mRNAs and proteins in cancer cell line, siRNAs are too expensive to manufacture and develop as anti-aging agent for skin to say nothing of their delivery challenge into the skin. Therefore, it is necessary to develop the pharmaceuticals or cosmetics based on the mechanism of ACC2 expression, which may improve and prevent skin aging condition.

Solution to the Problem

[0036] The present invention provides a peptide nucleic acid (PNA) derivative represented by **Formula I,** or a pharmaceutically acceptable salt thereof, for inducing exon skipping within human ACC2 pre-mRNA:

[Formula I]



wherein,

n is an integer between 10 and 17;
the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 18-mer pre-mRNA sequence of [(5' → 3') GGCCAUUUCGUCAGUAUC] in the human ACC2 pre-mRNA;
the compound of **Formula I** is fully complementary to exon/intron junction of the human ACC2 pre-mRNA;
S_1, S_2, •••, S_{n-1}, S_n, T_1, T_2, •••, T_{n-1}, and T_n independently represent hydrido radical;
X and Y independently represent hydrido or substituted or non-substituted alkyloxycarbonyl radical;
Z represents substituted or non-substituted amino radical;
B_1, B_2, •••, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; and,
at least four of B_1, B_2, •••, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II, Formula III, or Formula IV:**

[Formula II] [Formula III] [Formula IV]



wherein,

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;
L_1, L_2 and L_3 are a covalent linker represented by **Formula V** covalently linking the basic amino group to the nucleobase moiety:

[Formula V]



wherein,

Q_1 and Q_m are substituted or non-substituted methylene (-CH_2-) radical, and Q_m is directly linked to the basic amino group;
Q_2, Q_3, •••, and Q_{m-1} are independently selected from substituted or non-substituted methylene, and oxygen (-O-), radical; and
m is an integer between 1 and 15.

[0037] The compound of **Formula I** induces the skipping of "exon 12" in the human ACC2 pre-mRNA, yields the human ACC2 mRNA splice variant(s) lacking "exon 12", and therefore is useful to inhibit the functional activity of the gene transcribing the human ACC2 pre-mRNA.

[0038] The condition that "n is an integer between 10 and 17" literally means that n is an integer selectable from a group of integers of 11, 12, 13, 14, 15 and 16 .

[0039] The chemical structures of natural or unnatural nucleobases in the PNA derivative of **Formula I** are exemplified in Figures 1a-1c. Natural (i.e. naturally occurring) or unnatural (naturally non-occurring) nucleobases of this invention comprise but are not limited to the nucleobases provided in Figures 1a-1c. Provision of such unnatural nucleobases is to illustrate the diversity of allowable nucleobases, and therefore should not be interpreted to limit the scope of the present invention.

[0040] The substituents adopted to describe the PNA derivative of **Formula I** are exemplified in Figures 2a-2e. Figure 2a provides examples for substituted or non-substituted alkyl radicals. Substituted or non-substituted alkylacyl and substituted or non-substituted aryl acyl radicals are exemplified in Figure 2b. Figure 2c illustrates examples for substituted or non-substituted alkylamino, substituted or non-substituted arylamino, substituted or non-substituted aryl, substituted or non-substituted alkylsulfonyl or arylsulfonyl, and substituted or non-substituted alkylphosphonyl or arylphosphonyl radicals. Figure 2d provides examples for substituted or non-substituted alkyloxycarbonyl or aryloxycarbonyl, substituted or non-substituted alkyl aminocarbonyl or arylaminocarbonyl radicals. In Figure 2e are provided examples for substituted or non-substituted alkylaminothiocarbonyl, substituted or non-substituted arylaminothiocarbonyl, substituted or non-substituted alkyloxythiocarbonyl, and substituted or non-substituted aryloxythiocarbonyl radicals. Provision of such exemplary substituents is to illustrate the diversity of allowable substituents, and therefore should not be interpreted to limit the scope of the present invention. A skilled person in the field may easily figure out that oligonucleotide sequence is the overriding factor for sequence specific binding of oligonucleotide to the target pre-mRNA sequence over substituents in the N-terminus or C-terminus.

[0041] The compound of **Formula I** tightly binds to the complementary DNA as exemplified in the prior art [WO2009113828]. The duplex between the PNA derivative of **Formula I** and its full-length complementary DNA or RNA possesses a T_m value too high to be reliably determined in aqueous buffer. The PNA compound of **Formula I** yields high T_m values with complementary DNAs of shorter length.

[0042] The compound of **Formula I** complementarily binds to the 5' splice site of "exon 12" of the human ACC2 pre-mRNA. [NCBI Reference Sequence: NG_046907]. The 16-mer sequence of [(5'→3') GCCAUUUCGUCAGUAU] spans the junction of "exon 12" and "intron 12" in the human ACC2 pre-mRNA, and consists of 8-mer from " exon 12" and 8-mer from " intron 12". Thus the 16-mer pre-mRNA sequence may be conventionally denoted as [(5'→3') GCCAUUUC | gucaguau], wherein the exon and intron sequence are provided as "capital " and "small" letters, respectively, and the exon-intron junction is expressed with " | ". The conventional denotation for pre-mRNA is further illustrated by a 30-mer sequence of [(5'→3') GGAAGAGGCCAUUUC | gucaguaucuccuuc] spanning the junction of "exon 12" and "intron 12" in the human ACC2 pre-mRNA.

[0043] The compound of **Formula I** tightly binds to the target 5' splice site of the human ACC2 pre-mRNA transcribed

from the human ACC2 gene, and interferes with the formation of "spliceosome early complex" to yield ACC2 mRNA splice variant(s) lacking "exon 12" (exon 12 skipping).

[0044] The strong RNA affinity allows the compound of **Formula I** to induce the skipping of ACC2 "exon 12", even when the PNA derivative possesses one or two mismatches with the target 5' splice site in the ACC2 pre-mRNA. Similarly the PNA derivative of **Formula I** may still induce the skipping of ACC2 "exon 12" in a ACC2 mutant pre-mRNA possessing one or two SNPs (single nucleotide polymorphism) in the target splice site.

[0045] The compound of **Formula I** possesses good cell permeability and can be readily delivered into cell as "naked" oligonucleotide as exemplified in the prior art [PCT/KR2009/001256]. Thus the compound of this invention induces the skipping of "exon 12" in the ACC2 pre-mRNA, and yields ACC2 mRNA splice variant(s) lacking ACC2 "exon 12" in cells treated with the compound of **Formula I** as "naked" oligonucleotide. The compound of **Formula I** does not require any means or formulations for delivery into cell to potently induce the skipping of the target exon in cells. The compound of **Formula I** readily induces the skipping of ACC2 "exon 12" in cells treated with the compound of this invention as "naked" oligonucleotide at sub-femtomolar concentration.

[0046] Owing to the good cell or membrane permeability, the PNA derivative of **Formula I** can be topically administered as "naked" oligonucleotide to induce the skipping of ACC2 "exon 12" in the skin. The compound of **Formula I** does not require a formulation to increase trans-dermal delivery into target tissue for the intended therapeutic or biological activity. Usually the compound of **Formula I** is dissolved in water and co-solvent, and topically or trans-dermally administered at subpicomolar concentration to elicit the desired therapeutic or biological activity in target skin. The compound of this invention does not need to be heavily or invasively formulated to elicit the topical therapeutic activity. Nevertheless, the PNA derivative of **Formula I** can be formulated with cosmetic ingredients or adjuvants as topical cream or lotion. Such topical cosmetic cream or lotion may be useful to treat skin aging.

[0047] The compound of the present invention can be topically administered to a subject at a therapeutically or biologically effective concentration ranging from 1 aM to higher than 1 nM, which would vary depending on the dosing schedule, conditions or situations of the subject, and so on.

[0048] The PNA derivative of **Formula I** can be variously formulated including but not limited to injections, nasal spray, transdermal patch, and so on. In addition, the PNA derivative of **Formula I** can be administered to the subject at therapeutically effective dose and the dose of administration can be diversified depending on indication, administration route, dosing schedule, conditions or situations of the subject, and so on.

[0049] The compound of **Formula I** may be used as combined with a pharmaceutically acceptable acid or base including but not limited to sodium hydroxide, potassium hydroxide, hydrochloric acid, methanesulfonic acid, citric acid, trifluoroacetic acid, and so on.

[0050] The PNA derivative of **Formula I** or a pharmaceutically acceptable salt thereof can be administered to a subject in combination with a pharmaceutically acceptable adjuvant including but not limited to citric acid, hydrochloric acid, tartaric acid, stearic acid, polyethyleneglycol, polypropyleneglycol, ethanol, isopropanol, sodium bicarbonate, distilled water, preservative(s), and so on.

[0051] Of higher interest is a PNA derivative of **Formula I,** or a pharmaceutically acceptable salt thereof:
wherein,

n is an integer between 11 and 15;
the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 18-mer pre-mRNA sequence of [(5' → 3') GGCCAUUUCGUCAGUAUC] in the human ACC2 pre-mRNA;
the compound of **Formula I** is fully complementary to exon/intron junction of the human ACC2 pre-mRNA;
S_1, S_2, •••, S_{n-1}, S_n, T_1, T_2, •••, T_{n-1}, and T_n are hydrido radical;
X is hydrido radical;
Y represents substituted or non-substituted alkyloxycarbonyl radical;
Z represents substituted or non-substituted amino radical;
B_1, B_2, •••, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases;
at least five of B_1, B_2, •••, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II, Formula III,** or **Formula IV;**
R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;
L_1 represents $-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_3-$, $-CH_2-O-(CH_2)_4-$, or $-CH_2-O-(CH_2)_5-$; and,
L_2 and L_3 are independently selected from $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_3-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, and $-(CH_2)_8-$.

[0052] Of specific interest is a PNA derivative of **Formula I** which is selected from the group of compounds provided below (Hereinafter referred to as ASOs 1, 2, 3, 4, 5 and 6, respectively), or a pharmaceutically acceptable salt thereof:

(N→C) Fethoc-CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2;
(N→C) Fethoc-TA(5)C(1O2)-TGA(5)-CGA(5)-AA(5)T-G(6)GC(1O2)-C-NH_2;
(N→C) Fethoc-TA(5)C-TG(5)A-C(1O2)GA(5)-AA(5)T-G(5)G-NH_2;
(N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-C(1O2)C-NH_2 wherein,
A, G, T, and C are PNA monomers with a natural nucleobase of adenine, thymine, guanine and cytosine, respectively;
C(pOq), A(p), and G(p) are PNA monomers with an unnatural nucleobase represented by **Formula VI, Formula VII,** and **Formula VIII,** respectively;

[Formula VI] [Formula VII] [Formula VIII]



wherein,

p and q are integers, for example, p is 1 or 5 and q is 2 in case of ASO 4; and,
"Fethoc-" is the abbreviation for "[2-(9-fluorenyl)ethyl-1-oxy]carbonyl" and "-NH_2" is for non-substituted "-amino" group.

[0053] Figure 3 collectively and unambiguously provides the chemical structures for the PNA monomers abbreviated as A, G, T, C, C(pOq), A(p), and G(p). As discussed in the prior art [WO2009113828], C(pOq) is regarded as a "modified cytosine" PNA monomer due to its hybridization for "guanine". A(p) is taken as "modified adenine" PNA monomers due to their hybridization for "thymine", and G(p) is taken as "modified guanine" PNA monomers due to their hybridization for "cytosine". In addition, in order to illustrate the abbreviations employed for such PNA derivatives, the chemical structure of ASO 1 "(N → C) CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2" is provided in Figures 4.

[0054] ASO 1 is equivalent to the DNA sequence of "(5' → 3') CTG-ACG-AAA-TGG-CC" for complementary binding to pre-mRNA. The 14-mer PNA has a 14-mer complementary overlap with the 14-mer sequence marked "bold" and "underlined" within the 30-mer RNA sequence of [(5' → 3') GGAAGA**GGCCAUUUC** | **gucag**uaucuccuuc] spanning the junction of "exon 12" and "intron 12" in the human ACC2 pre-mRNA.

[0055] In some embodiments, the present invention provides the peptide nucleic acid derivative set out above, or a pharmaceutically acceptable salt thereof for use in a method of treating conditions or disorders associated with human ACC2 gene transcription in a subject, comprising administering to the subject the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

[0056] In some embodiments, the present invention provides the peptide nucleic acid derivative defined above, or a pharmaceutically acceptable salt thereof for use in a method of treating skin aging in a subject, comprising administering to the subject the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

[0057] In some embodiments, the present invention provides a pharmaceutical composition for treating conditions or disorders associated with human ACC2 gene transcription, comprising the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

[0058] In some embodiments, the present invention provides a cosmetic composition for treating conditions or disorders associated with human ACC2 gene transcription, comprising the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the present invention provides a pharmaceutical composition for treating skin aging, comprising the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

[0060] In some embodiments, the present invention provides a cosmetic composition for treating skin aging, comprising the peptide nucleic acid derivative of the present invention or a pharmaceutically acceptable salt thereof.

Effect of Invention

[0061] Conditions or disorders associated with human ACC2 gene transcription can be treated by administering a PNA derivative of **Formula I** or a pharmaceutically acceptable salt thereof.

[0062] Skin aging can be treated by administering a PNA derivative of **Formula I** or a pharmaceutically acceptable salt thereof.

Brief Explanation of Drawings

[0063]

Figures 1a-1c. Examples of natural or unnatural (modified) nucleobases selectable for the peptide nucleic acid derivative of **Formula I** not according to the invention, except substituted or non-substituted alkyloxycarbonyl.
Figures 2a-2e. Examples of substituents selectable for the peptide nucleic acid derivative of **Formula I** not according to the invention, except substituted or non-substituted alkyloxycarbonyl.
Figure 3. Chemical structures of PNA monomers with natural or modified nucleobase.
Figure 4. Chemical structure of "ASO 1".
Figure 5. Chemical structures of Fmoc-PNA monomers used to synthesize the PNA derivatives of this invention.
Figures 6a-6b. C_{18}-reverse phase HPLC chromatograms of "ASO 1" before and after HPLC purification, respectively.
Figure 7. ESI-TOF mass spectrum of "ASO 1" purified by C_{18}-RP prep HPLC.
Figure 8. Exon Skipping of ACC2 mRNA by "ASO 1" in C2C12.
Figure 9. Inhibition of ACC2 mRNA Levels by "ASO 1" in C2C12.
Figure 10. Inhibition of ACC2 mRNA Levels by "ASO 6" in C2C12.
Figure 11. Inhibition of ACC2 mRNA Levels by "ASO 5" in C2C12.

Best mode for carrying out the invention

General Procedures for Preparation of PNA Oligomers

[0064] PNA oligomers were synthesized by solid phase peptide synthesis (SPPS) based on Fmoc-chemistry according to the method disclosed in the prior art [US6,133,444; WO96/40685] with minor but due modifications. Fmoc is {(9-fluorenyl)methyloxy}carbonyl. The solid support employed in this study was H-Rink Amide-ChemMatrix purchased from PCAS BioMatrix Inc. (Quebec, Canada). Fmoc-PNA monomers with a modified nucleobase were synthesized as described in the prior art [PCT/KR 2009/001256] or with minor modifications. Such Fmoc-PNA monomers with a modified nucleobase and Fmoc-PNA monomers with a naturally occurring nucleobase were used to synthesize the PNA derivatives of the present invention. PNA oligomers were purified by C_{18}-reverse phase HPLC (water/acetonitrile or water/methanol with 0.1% TFA) and characterized by mass spectrometry including ESI/TOF/MS.

[0065] Scheme 1 illustrates a typical monomer elongation cycle adopted in the SPPS of this study, and the synthetic details are provided as below. To a skilled person in the field, however, there are lots of minor variations obviously possible in effectively running such SPPS reactions on an automatic peptide synthesizer or manual peptide synthesizer. Each reaction step in **Scheme 1** is briefly provided as follows.

[Scheme 1]



[0066] [Activation of H-Rink-ChemMatrix Resin] When the amine on the resin was not protected with Fmoc, 0.01 mmol (ca 20 mg resin) of the ChemMatrix resin in 1.5 mL 20% piperidine/DMF was vortexed in a libra tube for 20 min, and the DeFmoc solution was filtered off. The resin was washed for 30 sec each in series with 1.5 mL methylene chloride (MC), 1.5 mL dimethylformamide (DMF), 1.5 mL MC, 1.5 mL DMF, and 1.5 mL MC. The resulting free amines on the solid support were subjected to coupling with an Fmoc-PNA monomer.

[0067] [DeFmoc] When the amine on the resin was protected with Fmoc, the suspension of 0.01 mmol (ca 20 mg) of the resin in 1.5 mL 20% piperidine/DMF was vortexed for 7 min, and the DeFmoc solution was filtered off. The resin was washed for 30 sec each in series with 1.5 mL MC, 1.5 mL DMF, 1.5 mL MC, 1.5 mL DMF, and 1.5 mL MC. The resulting free amines on the solid support were immediately subjected to coupling with an Fmoc-PNA monomer.

[0068] [Coupling with Fmoc-PNA Monomer] The free amines on the solid support were coupled with an Fmoc-PNA monomer as follows. 0.04 mmol of PNA monomer, 0.05 mmol HBTU, and 0.1 mmol DIEA were incubated for 2 min in 1 mL anhydrous DMF, and added to the resin with free amines. The resin solution was vortexed for 1 hour and the reaction medium was filtered off. Then the resin was washed for 30 sec each in series with 1.5 mL MC, 1.5 mL DMF, and 1.5 mL MC. The chemical structures of Fmoc-PNA monomers with a modified nucleobase used in this invention are provided in Figure 5. The Fmoc-PNA monomers with a modified nucleobase are provided in Figure 5 should be taken as examples, and therefore should not be taken to limit the scope of the present invention. A skilled person in the field may easily figure out a number of variations in Fmoc-PNA monomers to synthesize the PNA derivative of **Formula I.**

[0069] [Capping] Following the coupling reaction, the unreacted free amines were capped by shaking for 5 min in 1.5 mL capping solution (5% acetic anhydride and 6% 2,6-leutidine in DMF). Then the capping solution was filtered off and washed for 30 sec each in series with 1.5 mL MC, 1.5 mL DMF, and 1.5 mL MC.

[0070] [Introduction of "Fethoc-" Radical in N-Terminus] "Fethoc-" radical was introduced to the N-terminus by reacting the free amine on the resin with "Fethoc-OSu" by the following method. The suspension of the resin in the solution of 0.1 mmol of Fethoc-OSu and 0.1 mmol DIEA in 1 mL anhydrous MDF was vortexed for 1 hr, and the solution was filtered off. The resin was washed for 30 sec each in series with 1.5 mL MC, 1.5 mL DMF, and 1.5 mL MC. The chemical structure of "Fethoc-OSu" [CAS No. 179337-69-0, $C_{20}H_{17}NO_5$, MW 351.36] used in the present invention is provided as follows.

Fethoc-OSu



[0071] [Cleavage from Resin] PNA oligomers bound to the resin were cleaved from the resin by shaking for 3 hours in 1.5 mL cleavage solution (2.5% tri-isopropylsilane and 2.5% water in trifluoroacetic acid). The resin was filtered off and the filtrate was concentrated under reduced pressure. The resulting residue was triturated with diethyl ether and the resulting precipitate was collected by filtration for purification by reverse phase HPLC.

[0072] [HPLC Analysis and Purification] Following a cleavage from resin, the crude product of a PNA derivative was purified by C_{18}-reverse phase HPLC eluting water/acetonitrile or water/methanol (gradient method) containing 0.1% TFA. Figures 6a and 6b are exemplary HPLC chromatograms for "ASO 1" before and after HPLC purification, respectively.

Synthetic Examples for PNA Derivative of Formula I

[0073] In order to complementarily target the 5' splice site of "exon 12" in the human ACC2 pre-mRNA, PNA derivatives of this invention were prepared according to the synthetic procedures provided above or with minor modifications. Provision of such PNA derivatives targeting the human ACC2 pre-mRNA is to exemplify the PNA derivatives of **Formula I,** and should not be interpreted to limit the scope of the present invention.

[Table 1] PNA derivatives complementarily targeting the 5' splice site of "exon 12" in the human ACC2 pre-mRNA along with structural characterization data by mass spectrometry.

PNA Exa mple	PNA Sequence (N→C)	Exact Mass, m/z	
		theor.[a]	obs.[b]
ASO 1	Fethoc-CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2	4549.07	4549.08
ASO 2	Fethoc-TA(5)C(1 02)-TGA(5)-CGA(5)-AA(5)T-G(6)GC(102)-C-NH_2	5289.43	5289.38
ASO 3	Fethoc-TA(5)C-TG(5)A-C(1O2)GA(5)-AA(5)T-G(5)G-NH_2	4661.14	4661.18
ASO 4	Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2	4658.11	4658.10
ASO 5	Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-NH_2	4047.86	4047.87
ASO 6	Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-C(1O2)C-NH_2	4647.12	4647.12
[a]theoretical exact mass, [b]observed exact mass			

[0074] Table 1 provides PNA derivatives complementarily targeting the 5' splice site of "exon 12" in the human ACC2 pre-mRNA read out from the human ACC2 gene [NCBI Reference Sequence: NG_046907] along with structural characterization data by mass spectrometry. Provision of the peptide nucleic acid derivatives of the present invention in Table 1 is to exemplify the PNA derivatives of **Formula I,** and should not be interpreted to limit the scope of the present invention.

[0075] "ASO 1" has a 14-mer complementary overlap with the 14-mer sequence marked "bold" and "underlined" within the 30-mer RNA sequence of [(5' → 3') GGAAGA**GGCCAUUUC** | **gucag**uaucuccuuc] spanning the junction of "exon 12" and "intron 12" in the human ACC2 pre-mRNA. Thus "ASO 1" possesses a 9-mer overlap with "exon 12" and a 5-

mer overlap with "intron 12" within the human ACC2 pre-mRNA.

Binding Affinity of "ASO" for Complementary DNA

[0076] The PNA derivatives of **Formula I** were evaluated for their binding affinity for 10-mer DNAs complementarily targeting either the N-terminal or C-terminal. The binding affinity was assessed by T_m value for the duplex between PNA and 10-mer complementary DNA. The duplex between PNA derivatives and fully complementary DNAs show T_m values too high to be reliably determined in aqueous buffer solution, since the buffer solution tends to boil during the T_m measurement. T_m values for full length PNAs can be predicted and compared based on the T_m value for the duplex between PNA and 10-mer complementary DNA.

[0077] T_m values were determined on a UV/Vis spectrometer as follows. A mixed solution of 4 μM PNA oligomer and 4 μM complementary 10-mer DNA in 4 mL aqueous buffer (pH 7.16, 10 mM sodium phosphate, 100 mM NaCl) in 15 mL polypropylene falcon tube was incubated at 90°C for a few minute and slowly cooled down to ambient temperature. Then the solution was transferred into a 3 mL quartz UV cuvette equipped with an air-tight cap, and the cuvette was mounted on an Agilent 8453 UV/Visible spectrophotometer. The absorbance changes at 260 nm were recorded with increasing the temperature of the cuvette by either 0.5 or 1°C per minute. From the absorbance vs temperature curve, the temperature showing the largest increase rate in absorbance was read out as the T_m between PNA and 10-mer DNA. The DNAs for T_m measurement were purchased from Bioneer (www.bioneer.com, Dajeon, Republic of Korea) and used without further purification.

[0078] Observed T_m values of the PNA derivatives of **Formula I** are very high for a complementary binding to 10-mer DNA as provided in Table 2.

[Table 2] T_m values between PNAs and 10-mer complementary DNA targeting either the N-terminal or the C-terminal of PNA.

PNA	T_m Value, °C	
	10-mer DNA against N-Terminal	10-mer DNA against C-Terminal
ASO 1	72.80	79.60
ASO 2	82.99	82.01
ASO 3	76.03	78.99
ASO 4	80.01	82.01

[0079] For example, "ASO 1" showed a T_m value of 72.80°C for the duplex with the 10-mer complementary DNA targeting the N-terminal 10-mer in the PNA as marked "bold" and "underlined" in [(N → C) Fethoc-**CTG(6)-ACG(6)-AA(5)A- T**G(6)G-C(1O2)C-NH_2]. In the meantime, "ASO 1" showed a T_m of 79.60°C for the duplex with the 10-mer complementary DNA targeting the C-terminal 10-mer in the PNA as marked "bold" and "underlined" in [(N → C) Fethoc-CTG(6)-A**CG(6)- AA(5)A- TG(6)G-C(1O2)C**-NH_2].

Examples for Biological Activities of PNA Derivatives of Formula I

[0080] PNA derivatives in this invention were evaluated for in vitro ACC2 antisense activities in C2C12 skeletal muscle cells by use of real-time quantitative polymerase chain reaction (RT-qPCR) and so on. The biological examples were provided as examples to illustrate the biological profiles of the PNA derivatives of **Formula I,** and therefore should not be interpreted to limit the scope of the current invention.

Example 1. Exon Skipping Induced by "ASO 1" in C2C12.

[0081] "ASO 1" was evaluated for its ability to induce the skipping of ACC2 "exon 12" in C2C12 cells as described below.

[0082] [Cell Culture & ASO Treatment] C2C12 cells (2×10^5) (Cat. No. CRL-1772, ATCC) were grown in 60 mm culture dish containing DMEM medium (Dulbecco Modified Eagle Medium: DMEM) (Cat. No. 12-604F, Lonza) supplemented with 10% FBS (Fetal Bovine Serum) (Cat. No. 10099-41, GIBCO) and 1% streptomycin/penicillin (Cat. No. 15140-122, GIBCO) under 5% CO_2 atmosphere at 37°C. The cells were treated either with nothing (negative control) or with an aliquot of aqueous stock solution of "ASO 1" for 5 hours at 100 zM to 1 fM.

[0083] [RNA Extraction & Nested PCR] Total RNA was extracted using RNeasy Mini kit (Qiagen, Cat. No. 714106) according to the manufacturer's instructions from "ASO 1" treated cells and cDNA was prepared from 200 ng of RNA

by use of SuperScript™ III One-Step RT-PCR System (Cat. No. 12574-018, Invitrogen). To a mixture of 200 ng of RNA, 25 microliter of 2X Reaction Mix buffer, 2 microliter of SuperScript III™ RT/Platinum Taq Mix, 1 microliter of 10 μM (micromole conc.) Exon 9 Forward Primer (5'-TTTTCCGACAAGTGCAGAG-3'), and 1 microliter of 10 μM Exon 15 Reverse Primer (5'-AACGTCCACAATGTTCAG-3') in PCR tube was added autoclaved distilled water to a total volume of 50 microliter. After reaction at 60°C for 30 minutes and at 94°C for 2 minutes, 30 cycles PCR process at 94°C for 15 seconds, at 50°C for 30 seconds, and at 68°C for 1 minute afforded the first crude product. The mixture of 1 microliter of the crude product, 1 microliter of 10 μM Exon 10 Forward Primer (5'-GAG TAC TTA TAC AGC CAG G-3'), and 1 microliter of 10 μM Exon 14 Reverse Primer (5'-TTC TGA ACA TCG CGT CTG-3') was reacted, using PyroHostStart Taq Polymerase Kit (Cat. No. K-2611-FCG) according to the manufacturer's instructions, at 95°C for 2 minutes, and then was under PCR process at 95°C for 30 seconds, at 47°C for 1 minute, and at 72°C for 20 seconds.

[0084] [Identification of Exon Skipping Products Electrophoresis] The PCR products (10 microliter) were subjected to electrophoretic separation on a 2% agarose gel. The target bands from "ASO 1" treatment were collected and analyzed by Sanger Sequencing to evaluate exon skipping sequence.

[0085] [Exon Skipping Induced by "ASO 1"] As can be seen in Figure 8, the cells treated with "ASO 1" at 0.1 aM to 1 fM concentration-dependently yielded the splice variant ACC2 mRNA lacking exon 11.

Example 2. Inhibition of ACC2 mRNA Formation by "ASO 1" in C2C12.

[0086] "ASO 1" was evaluated by Real-Time qPCR for its ability to down-regulate the ACC2 mRNA formation in C2C12 as described below.

[0087] [Cell Culture & ASO Treatment] C2C12 cells (Cat. No. CRL-1772, ATCC) were maintained in Dulbecco Modified Eagle Medium (DMEM, Cat. No. 12-604F, Lonza) supplemented with 10% Fetal Bovine Serum (Cat. No. 10099-41, GIBCO) and 1% streptomycin/penicillin (Cat. No. 15140-122, GIBCO), which was grown at 37°C and under 5% CO_2 condition. C2C12 cells (2×10^5) stabilized for 24 hours in 60 mm culture dish were incubated for 24 hours with "ASO 1" at 0 (negative control) and 100 zM to 1 fM.

[0088] [RNA Extraction & cDNA Synthesis] Total RNA was extracted using RNeasy Mini kit (Qiagen, Cat. No. 714106) according to the manufacturer's instructions from "ASO 1" treated cells and cDNA was prepared from 400 ng of RNA by use of PrimeScript™ 1st strand cDNA Synthesis Kit (Takara, Cat. No. 6110A). To a mixture of 400 ng of RNA, 1 microliter of random hexamer, and 1 microliter of dNTP (10 mM) in PCR tube was added DEPC-treated water to a total volume of 10 microliter, which was reacted at 65°C for 5 minutes. cDNA was synthesized by adding 10 microliter of PrimeScript RTase to the reaction mixture and reacting at 30°C for 10 minutes and at 42°C for 60 minutes, successively.

[0089] [Quantitative Real-Time PCR] In order to evaluate the expression level of human ACC2 mRNA real-time qPCR was performed with synthesized cDNA by use of Taqman probe. The mixture of cDNA, Taqman probe (Thermo, Mm01204651), IQ supermix (BioRad, Cat. No. 170-8862), and nuclease free water in PCR tube was under reaction by use of CFX96 Touch Real-Time system (BioRad) according to the cycle conditions specified as follows: at 95 °C for 3 min (primary denaturation) followed by 50 cycles of 10 sec at 95 °C (denaturation) and 30 sec at 60°C (annealing and polymerization). Fluorescence intensity was measured at the end of every cycle and the result of PCR was evaluated by the melting curve. After the threshold cycle (Ct) of each gene was standardized by that of GAPDH, the change of Ct was compared and analyzed.

[0090] [ACC2 mRNA Decrease by "ASO 1"] As can be seen in Figure 9, compared to control experiment the amount of ACC2 mRNA was reduced at 100 zM to 1 fM treatment of "ASO 1", concentration-dependently, and statistically significant 30% of reduction was observed at 1fM treatment of "ASO 1". (Student T-test was done to check the statistical significance of the findings)

Example 3. Inhibition of ACC2 mRNA Formation by "ASO 6" in C2C12.

[0091] "ASO 6" was evaluated by Real-Time qPCR for its ability to down-regulate the ACC2 mRNA formation in C2C12 as described below.

[0092] [Cell Culture & ASO Treatment] C2C12 cells (Cat. No. CRL-1772, ATCC) were maintained in Dulbecco Modified Eagle Medium (DMEM, Cat. No. 12-604F, Lonza) supplemented with 10% Fetal Bovine Serum (Cat. No. 10099-41, GIBCO) and 1% streptomycin/penicillin (Cat. No. 15140-122, GIBCO), which was grown at 37°C and under 5% CO_2 condition. C2C12 cells (2×10^5) stabilized for 24 hours in 60 mm culture dish were incubated for 24 hours with "ASO 6" at 0 (negative control) and 100 zM to 1 fM.

[0093] [RNA Extraction & cDNA Synthesis] Total RNA was extracted using RNeasy Mini kit (Qiagen, Cat. No. 714106) according to the manufacturer's instructions from "ASO 6" treated cells and cDNA was prepared from 400 ng of RNA by use of PrimeScript™ 1st strand cDNA Synthesis Kit (Takara, Cat. No. 6110A). To a mixture of 400 ng of RNA, 1 microliter of random hexamer, and 1 microliter of dNTP (10 mM) in PCR tube was added DEPC-treated water to a total volume of 10 microliter, which was reacted at 65°C for 5 minutes. cDNA was synthesized by adding 10 microliter of

PrimeScript RTase to the reaction mixture and reacting at 30°C for 10 minutes and at 42°C for 60 minutes, successively.

[0094] [Quantitative Real-Time PCR] In order to evaluate the expression level of human ACC2 mRNA real-time qPCR was performed with synthesized cDNA by use of Taqman probe. The mixture of cDNA, Taqman probe (Thermo, Mm01204651), IQ supermix (BioRad, Cat. No. 170-8862), and nuclease free water in PCR tube was under reaction by use of CFX96 Touch Real-Time system (BioRad) according to the cycle conditions specified as follows: at 95°C for 3 min (primary denaturation) followed by 50 cycles of 10 sec at 95 °C (denaturation) and 30 sec at 60 °C (annealing and polymerization). Fluorescence intensity was measured at the end of every cycle and the result of PCR was evaluated by the melting curve. After the threshold cycle (Ct) of each gene was standardized by that of GAPDH, the change of Ct was compared and analyzed.

[0095] [ACC2 mRNA Decrease by "ASO 6"] As can be seen in Figure 10, the amount of ACC2 mRNA was reduced at 100 zM to 1 fM treatment of "ASO 6", concentration-dependently. Compared to the control experiment, statistically significant 30% and 50% reduction was observed at 1 aM and 1fM treatment of "ASO 6", respectively. (Student T-test was done to check the statistical significance of the findings)

Example 4. Inhibition of ACC2 mRNA Formation by "ASO 5" in C2C12.

[0096] "ASO 5" was evaluated by the same method as described below.

[0097] [Cell Culture & ASO Treatment] C2C12 cells (Cat. No. CRL-1772, ATCC) were maintained in Dulbecco Modified Eagle Medium (DMEM, Cat. No. 12-604F, Lonza) supplemented with 10% Fetal Bovine Serum (Cat. No. 10099-41, GIBCO) and 1% streptomycin/penicillin (Cat. No. 15140-122, GIBCO), which was grown at 37°C and under 5% CO_2 condition. C2C12 cells (2×10^5) stabilized for 24 hours in 60 mm culture dish were incubated for 24 hours with "ASO 5" at 0 (negative control) and 100 zM to 1 fM.

[0098] [RNA Extraction & cDNA Synthesis] Total RNA was extracted using RNeasy Mini kit (Qiagen, Cat. No. 714106) according to the manufacturer's instructions from "ASO 5" treated cells and cDNA was prepared from 400 ng of RNA by use of PrimeScript™ 1st strand cDNA Synthesis Kit (Takara, Cat. No. 6110A). To a mixture of 400 ng of RNA, 1 microliter of random hexamer, and 1 microliter of dNTP (10 mM) in PCR tube was added DEPC-treated water to a total volume of 10 microliter, which was reacted at 65°C for 5 minutes. cDNA was synthesized by adding 10 microliter of PrimeScript RTase to the reaction mixture and reacting at 30°C for 10 minutes and at 42°C for 60 minutes, successively.

[0099] [Quantitative Real-Time PCR] In order to evaluate the expression level of human ACC2 mRNA real-time qPCR was performed with synthesized cDNA by use of Taqman probe. The mixture of cDNA, Taqman probe (Thermo, Mm01204651), IQ supermix (BioRad, Cat. No. 170-8862), and nuclease free water in PCR tube was under reaction by use of CFX96 Touch Real-Time system (BioRad) according to the cycle conditions specified as follows: at 95°C for 3 min (primary denaturation) followed by 50 cycles of 10 sec at 95 °C (denaturation) and 30 sec at 60 °C (annealing and polymerization). Fluorescence intensity was measured at the end of every cycle and the result of PCR was evaluated by the melting curve. After the threshold cycle (Ct) of each gene was standardized by that of GAPDH, the change of Ct was compared and analyzed.

[0100] [ACC2 mRNA Decrease by "ASO 5"] As can be seen in Figure 11, the amount of ACC2 mRNA was reduced at 100 zM to 1 fM treatment of "ASO 5", concentration-dependently. Compared to the control experiment, statistically significant 30% and 42% reduction was observed at 1 aM and 1fM treatment of "ASO 5", respectively. (Student T-test was done to check the statistical significance of the findings)

Example 5. Preparation of Body Lotion Containing Compound of **Formula I.** (w/w%)

[0101] A compound of **Formula I,** for example "ASO 1" was formulated as a body lotion for topical application to subjects. The body lotion was prepared as described below. Given that there are lots of variations of body lotion possible, this preparation should be taken as an example and should not be interpreted to limit the scope of the current invention.

[0102] In a separate beaker, mixed substances of part A and part B were dissolved at 80°C, respectively. Part A and part B was mixed and emulsified by use of 3,600 rpm homogenizer at 80°C for 5 minutes. Emulsified part C was filtered through 50 mesh and the filtrate was added to the mixture of part A and B. The resulting mixture was emulsified by use of 3,600 rpm homogenizer at 80°C for 5 minutes. After addition of part D to the mixture of part A, B, and C at 35°C, the resulting mixture was emulsified by use of 2,500 rpm homogenizer at 25°C for 3 minutes. Finally make sure homogeneous dispersion and complete defoamation.

[Table 3] Example of Composition for Body Lotion Containing Compound of **Formula I.** (w/w%)

Part	No.	Substance Name	Amount (%/%)
A	1	Polyglyceryl-3 Methylglucose Distearate	0.700
	2	Glyceryl Stearate	0.300
	3	Cetearyl Alcohol	1.000
	4	Shea Butter	1.000
	5	Caprylic/ Capric Triglyceride	3.000
	6	Dicaprylyl Carbonate	4.000
	7	Dimethicone	0.500
	8	Ethylhexylglycerin	0.300
B	9	Glycerin	5.000
	10	Propanediol	5.000
	11	1,2-Hexanediol	0.300
	12	Arginine	0.160
	13	Deionized Water	62.110
C	14	Sodium Acrylate/Sodium Acryloyldimethyl Tau Copolymer	0.300
	15	Carbomer	0.200
	16	Xanthan Gum	0.030
	17	Deionized Water	13.000
D	18	Perfume	0.100
	19	Oligomer [1000fM] + POLYSORBATE 80 [0.1%]	3.000
SUM			100.000

Example 6. Preparation of Face Cream Containing Compound of **Formula I.** (w/w%)

[0103] A compound of **Formula I,** for example "ASO 1" was formulated as a face cream for topical application to subjects. The face cream was prepared as described below. Given that there are lots of variations of topical cream possible, this preparation should be taken as an example and should not be interpreted to limit the scope of the current invention.

[Table 4] Example of Composition for Face Cream Containing Compound of **Formula I.** (w/w%)

Part	No.	Substance Name	Amount (%/%)
A	1	Caprylic/ Capric Triglyceride	2.000
	2	Glyceryl Stearate / Polyglyceryl-10 Stearate	10.000
	3	Cetearyl Alcohol	2.000
	4	Ethylhexylglycerin	0.300
B	10	Glycerin	5.000
	11	1,2-Hexanediol	0.300
	12	Deionized Water	78.900
C	14	Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Tau Copolymer	1.000
D	19	Oligomer [1000fM] + POLYSORBATE 80 [0.1%]	0.500

(continued)

Part	No.	Substance Name	Amount (%/%)
SUM			100.000

[0104] In a separate beaker, mixed substances of part A and part B were dissolved at 80°C, respectively. Part A and part B was mixed and emulsified by use of 3,600 rpm homogenizer at 80°C for 5 minutes. After addition of part C to the mixture of part A and B, the resulting mixture was emulsified by use of 3,600 rpm homogenizer at 80°C for 5 minutes. After addition of part D to the mixture of part A, B, and C at 35 °C, the resulting mixture was emulsified by use of 3,600 rpm homogenizer at 35°C for 5 minutes. Finally make sure homogeneous dispersion and complete defoamation at 25°C.

Claims

1. A peptide nucleic acid derivative represented by **Formula I,** or a pharmaceutically acceptable salt thereof, for inducing exon skipping within human ACC2 (acetyl-CoA carboxylase 2) pre-mRNA:

[Formula I]



wherein,

n is an integer between 11 and 17;
the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 18-mer pre-mRNA sequence of [(5' → 3') GGCCAUUUCGUCAGUAUC] in the human ACC2 pre-mRNA;
the compound of **Formula I** is fully complementary to exon/intron junction of the human ACC2 pre-mRNA;
S_1, S_2, •••, S_{n-1}, S_n, T_1, T_2, •••, T_{n-1}, and T_n are hydrido radical;
X and Y independently represent hydrido or substituted or non-substituted alkyloxycarbonyl radical;
Z represents substituted or non-substituted amino radical;
B_1, B_2, •••, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; and,
at least four of B_1, B_2, •••, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II, Formula III,** or **Formula IV:**

[Formula II]



[Formula III]



[Formula IV]



wherein,

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;
L_1, L_2 and L_3 are a covalent linker represented by **Formula V** covalently linking the basic amino group to the nucleobase moiety:

[Formula V]



wherein,

Q_1 and Q_m are substituted or non-substituted methylene ($-CH_2-$) radical, and Q_m is directly linked to the basic amino group;
Q_2, Q_3, •••, and Q_{m-1} are independently selected from substituted or non-substituted methylene, and oxygen (-O-), radical; and
m is an integer between 1 and 15.

2. The peptide nucleic acid derivative according to claim 1, or a pharmaceutical salt thereof: wherein,

n is an integer between 11 and 15;
the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 18-mer pre-mRNA sequence of [(5' → 3') GGCCAUUUCGUCAGUAUC] in the human ACC2 pre-mRNA;
the compound of **Formula I** is fully complementary to exon/intron junction of the human ACC2 pre-mRNA;
S_1, S_2, •••, S_{n-1}, S_n, T_1, T_2, •••, T_{n-1}, and T_n are hydrido radical;
X is hydrido radical;
Y represents substituted or non-substituted alkyloxycarbonyl radical;
Z represents substituted or non-substituted amino radical;
B_1, B_2, •••, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases;
at least five of B_1, B_2, •••, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II, Formula III,** or **Formula IV;**
R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;
L_1 represents $-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_3-$, $-CH_2-O-(CH_2)_4-$, or $-CH_2-O-(CH_2)_5-$; and,
L_2 and L_3 are independently selected from $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_3-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, and $-(CH_2)_8-$.

3. The peptide nucleic acid derivative according to claim 2, which is selected from the group of peptide nucleic acid derivatives provided below, or a pharmaceutically acceptable salt thereof:

(N→C) Fethoc-CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2;
(N→C) Fethoc-TA(5)C(1O2)-TGA(5)-CGA(5)-AA(5)T-G(6)GC(1O2)-C-NH_2;
(N→C) Fethoc-TA(5)C-TG(5)A-C(1O2)GA(5)-AA(5)T-G(5)G-NH_2;
(N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-C(1O2)C-NH_2 wherein,
A, G, T, and C are monomers of peptide nucleic acid with a natural nucleobase of adenine, thymine, guanine and cytosine, respectively;
C(pOq), A(p), and G(p) are monomers of peptide nucleic acid with an unnatural nucleobase represented by **Formula VI, Formula VII,** and **Formula VIII,** respectively;

[Formula VI] [Formula VII] [Formula VIII]



wherein,

p and q are integers, and p is 1 or 5 and q is 2 in (N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2; and
"Fethoc-" is the abbreviation for "[2-(9-fluorenyl)ethyl-1-oxy]carbonyl".

4. A peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof for use in a method to treat conditions or disorders associated with the human ACC2 gene transcription, comprising the administration of said peptide nucleic acid derivative, or said pharmaceutically acceptable salt thereof to a subject

5. A peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof for use in a method to treat skin aging, comprising the administration of said peptide nucleic acid derivative, or said pharmaceutically acceptable salt thereof to a subject

6. A pharmaceutical composition for treating conditions or disorders associated with human ACC2 gene transcription, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

7. A cosmetic composition for treating conditions or disorders associated with human ACC2 gene transcription, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition for treating skin aging, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

9. A cosmetic composition for treating skin aging, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

Patentansprüche

1. Peptidnukleinsäurederivat dargestellt durch **Formel I,** oder pharmazeutisch verträgliches Salz davon zum Induzieren von Exon-Skipping innerhalb von humaner ACC2(Acetyl-CoA-Carboxylase 2-)Prä-mRNA:

[Formel I]



wobei

n eine ganze Zahl zwischen 11 und 17 ist;
die Verbindung von **Formel I** zumindest eine komplementäre 10-mer-Überlappung mit der 18-mer-Prä-mRNA-Sequenz von [(5' → 3') GGCCAUUUCGUCAGUAUC] in der humanen ACC2-Prä-mRNA besitzt;
die Verbindung der **Formel I** vollständig komplementär zu Exon/Intron-Verbindung der humanen ACC2-Prä-mRNA ist;
S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1} und T_n Hydridorest sind;
X und Y unabhängig Hydrido oder substituierten oder unsubstituierten Alkyloxycarbonylrest darstellen;
Z substituierten oder unsubstituierten Aminorest darstellt;
B_1, B_2, ···, B_{n-1} und B_n unabhängig aus natürlichen Nukleobasen, die Adenin, Thymin, Guanin, Cytosin und Uracil beinhalten, und unnatürlichen Nukleobasen ausgewählt sind; und
zumindest vier von B_1, B_2, ···, B_{n-1} und B_n unabhängig aus unnatürlichen Nukleobasen dargestellt durch **Formel II, Formel III** oder **Formel IV** ausgewählt sind:

[Formel II] [Formel III] [Formel IV]



wobei

R_1, R_2, R_3, R_4, R_5 und R_6 Hydridorest sind;
Li, L_2 und L_3 ein kovalenter Linker sind, der durch **Formel V** dargestellt ist, der die basische Aminogruppe kovalent mit der Nukleobaseneinheit verbindet:

[Formel V]



wobei

Q_1 und Q_m substituierter oder unsubstituierter Methylen(-CH_2-)Rest sind und Q_m direkt mit der basischen Aminogruppe verbunden ist;
Q_2, Q_3, ···, und Q_{m-1} unabhängig aus substituiertem oder unsubstituiertem Methylen- und Sauerstoff(-O-)Rest ausgewählt sind; und
m eine ganze Zahl zwischen 1 und 15 ist.

2. Peptidnukleinsäurederivat nach Anspruch 1 oder pharmazeutisches Salz davon: wobei

n eine ganze Zahl zwischen 11 und 15 ist;
die Verbindung von **Formel I** zumindest eine komplementäre 10-mer-Überlappung mit der 18-mer-Prä-mRNA-

Sequenz von [(5' → 3') GGCCAUUUCGUCAGUAUC] in der humanen ACC2-Prä-mRNA besitzt;
die Verbindung der **Formel I** vollständig komplementär zu Exon/Intron-Verbindung der humanen ACC2-Prä-mRNA ist;
S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1} und T_n Hydridorest sind;
X Hydridorest ist;
Y substituierten oder unsubstituierten Alkyloxycarbonylrest darstellt;
Z substituierten oder unsubstituierten Aminorest darstellt;
B_1, B_2, ···, B_{n-1} und B_n unabhängig aus natürlichen Nukleobasen, die Adenin, Thymin, Guanin, Cytosin und Uracil beinhalten, und unnatürlichen Nukleobasen ausgewählt sind;
zumindest fünf von B_1, B_2, ···, B_{n-1} und B_n unabhängig aus unnatürlichen Nukleinbasen ausgewählt sind, die durch **Formel II, Formel III** oder **Formel IV** dargestellt sind;
R_1, R_2, R_3, R_4, R_5 und R_6 Hydridorest sind;
L_1 $-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_3-$, $-CH_2-O-(CH_2)_4-$ oder $-CH_2-O-(CH_2)_5-$ darstellt; und
L_2 und L_3 unabhängig aus $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_3-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$ und $-(CH_2)_8-$ ausgewählt sind.

3. Peptidnukleinsäurederivat nach Anspruch 2, das ausgewählt ist aus der Gruppe von Peptidnukleinsäurederivaten, die unten bereitgestellt ist, oder einem pharmazeutisch verträglichen Salz davon:

(N→C) Fethoc-CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2;
(N→C) Fethoc-TA(5)C(1O2)-TGA(5)-CGA(5)-AA(5)T-G(6)GC(1O2)-C-NH_2;
(N→C) Fethoc-TA(5)C-TG(5)A-C(1O2)GA(5)-AA(5)T-G(5)G-NH_2;
(N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-NH_2;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-C(1O2)C-NH_2 wobei
A, G, T und C jeweils Monomere von Peptidnukleinsäure mit einer natürlichen Nukleobase von Adenin, Thymin, Guanin und Cytosin sind;
C(pOq), A(p) und G(p) Monomere von Peptidnukleinsäure mit einer unnatürlichen Nukleobase sind, die jeweils durch **Formel VI, Formel VII** und **Formel VIII** dargestellt sind;

[Formel VI]



[Formel VII]



[Formel VIII]



wobei

p und q ganze Zahlen sind, und p 1 oder 5 ist und q 2 in (N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2 ist; und
"Fethoc-" die Abkürzung für "[2-(9-Fluorenyl)ethyl-l-oxy]carbonyl" ist.

4. Peptidnukleinsäurederivat nach Anspruch 1 oder pharmazeutisch verträgliches Salz davon zur Verwendung in einem Verfahren zum Behandeln von Zuständen oder Störungen assoziiert mit der humanen ACC2-Gentranskription, umfassend die Verabreichung des Peptidnukleinsäurederivats oder des pharmazeutisch verträglichen Salzes davon an ein Subjekt.

5. Peptidnukleinsäurederivat nach Anspruch 1 oder pharmazeutisch verträgliches Salz davon zur Verwendung in einem Verfahren zum Behandeln von Hautalterung, umfassend die Verabreichung des Peptidnukleinsäurederivats oder des pharmazeutisch verträglichen Salzes davon an ein Subjekt.

6. Pharmazeutische Zusammensetzung zum Behandeln von Zuständen oder Störungen assoziiert mit humaner ACC2-Gentranskription, umfassend das Peptidnukleinsäurederivat nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon.

7. Kosmetische Zusammensetzung zum Behandeln von Zuständen oder Störungen assoziiert mit humaner ACC2-Gentranskription, umfassend das Peptidnukleinsäurederivat nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon.

8. Pharmazeutische Zusammensetzung zum Behandeln von Hautalterung, umfassend das Peptidnukleinsäurederivat nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon.

9. Kosmetische Zusammensetzung zum Behandeln von Hautalterung, umfassend das Peptidnukleinsäurederivat nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon.

Revendications

1. Dérivé d'acide nucléique peptidique représenté par la **Formule I,** ou sel pharmaceutiquement acceptable de celui-ci, destiné à induire un saut d'exon dans le pré-ARNm d'ACC2 (acétyl-CoA carboxylase 2) humain :

[Formule I]



dans lequel

n est un nombre entier entre 11 et 17 ;
le composé de **Formule I** possède au moins un chevauchement complémentaire de 10-mer avec la séquence d'un pré-ARNm de 18-mer de [(5' → 3') GGCCAUUUCGUCAGUAUC] dans le pré-ARNm d'ACC2 humain ;
le composé de **Formule I** est totalement complémentaire de la jonction exon/intron du pré-ARNm d'ACC2 humain ;
S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ··· , T_{n-1} et T_n sont un radical hydrido ;
X et Y représentent indépendamment un radical hydrido ou alkyloxycarbonyle substitué ou non substitué ;
Z représente un radical amino substitué ou non substitué ;
B_1, B_2, ··· , B_{n-1} et B_n sont indépendamment choisis parmi des nucléobases naturelles comprenant adénine, thymine, guanine, cytosine et uracile, et des nucléobases non naturelles ; et,
au moins quatre parmi B_1, B_2, ··· , B_{n-1} et B_n sont indépendamment choisis parmi des nucléobases non naturelles représentées par la **Formule II,** la **Formule III** ou la **Formule IV :**

[Formule II] [Formule III] [Formule IV]



dans lequel

R_1, R_2, R_3, R_4, R_5 et R_6 sont un radical hydrido ;
Li, L_2 et L_3 sont un lieur covalent représenté par la **Formule V** liant de manière covalente le groupe amino basique à la fraction de nucléobase :

[Formule V]



dans lequel

Q_1 et Q_m sont un radical méthylène ($-CH_2-$) substitué ou non substitué, et Q_m est directement lié au groupe amino basique ;
Q_2, Q_3, ··· et Q_{m-1} sont indépendamment choisis parmi un radical méthylène substitué ou non substitué, et oxygène (-O-) ; et
m est un nombre entier entre 1 et 15.

2. Dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutique de celui-ci : dans lequel

n est un nombre entier entre 11 et 15 ;
le composé de **Formule I** possède au moins un chevauchement complémentaire de 10-mer avec la séquence d'un pré-ARNm de 18-mer de [(5' → 3') GGCCAUUUCGUCAGUAUC] dans le pré-ARNm d'ACC2 humain ;
le composé de **Formule I** est totalement complémentaire de la jonction exon/intron du pré-ARNm d'ACC2 humain ;
S_1, S_2, ··· , S_{n-1}, S_n, T_1, T_2, ···, T_{n-1} et T_n sont un radical hydrido ;
X est un radical hydrido ;
Y représente un radical alkyloxycarbonyle substitué ou non substitué ;
Z représente un radical amino substitué ou non substitué ;
B_1, B_2, ··· , B_{n-1} et B_n sont indépendamment choisis parmi des nucléobases naturelles comprenant adénine, thymine, guanine, cytosine et uracile, et des nucléobases non naturelles ;
au moins cinq parmi B_1, B_2, ··· , B_{n-1} et B_n sont indépendamment choisis parmi des nucléobases non naturelles représentées par la **Formule II,** la **Formule III** ou la **Formule IV ;**
R_1, R_2, R_3, R_4, R_5 et R_6 sont un radical hydrido ;
L_1 représente $-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_3-$, $-CH_2-O-(CH_2)_4-$ ou $-CH_2-O-(CH_2)_5-$; et,
L_2 et L_3 sont indépendamment choisis parmi $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_3-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$ et $-(CH_2)_8-$.

3. Dérivé d'acide nucléique peptidique selon la revendication 2, qui est choisi dans le groupe des dérivés d'acide nucléique peptidique indiqués ci-dessous, ou sel pharmaceutiquement acceptable de celui-ci :

(N→C) Fethoc-CTG(6)-ACG(6)-AA(5)A-TG(6)G-C(1O2)C-NH_2 ;
(N→C) Fethoc-TA(5)C(1O2)-TGA(5)-CGA(5)-AA(5)T-G(6)GC(1O2)-C-NH_2 ;
(N→C) Fethoc-TA(5)C-TG(5)A-C(1O2)GA(5)-AA(5)T-G(5)G-NH_2 ;
(N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2 ;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-NH_2 ;
(N→C) Fethoc-CTG(6)-AC(1O2)G-A(5)AA(5)-TG(6)G-C(1O2)C-NH_2 dans lequel
A, G, T, et C sont des monomères d'acide nucléique peptidique avec une nucléobase naturelle d'adénine, de thymine, de guanine et de cytosine, respectivement ;
C(pOq), A(p) et G(p) sont des monomères d'acide nucléique peptidique avec une nucléobase non naturelle représentée par la **Formule VI,** la **Formule VII** et la **Formule VIII,** respectivement ;

[Formule VI]



[Formule VII]



[Formule VIII]



dans lequel

p et q sont des nombres entiers, et p est 1 ou 5 et q est 2 dans (N→C) Fethoc-AC(1O2)T-GA(5)C-GA(5)A-A(5)TG(5)-GC(1O2)-NH_2 ; et
« Fethoc- » est l'abréviation de « [2-(9-fluorényl)éthyl-1-oxy]carbonyle ».

4. Dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans un procédé de traitement d'états ou de troubles associés à la transcription du gène ACC2 humain, comprenant l'administration dudit dérivé d'acide nucléique peptidique ou dudit sel pharmaceutiquement acceptable de celui-ci à un sujet.

5. Dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans un procédé de traitement du vieillissement de la peau, comprenant l'administration dudit dérivé d'acide nucléique peptidique ou dudit sel pharmaceutiquement acceptable de celui-ci à un sujet.

6. Composition pharmaceutique destinée à traiter des états ou des troubles associés à la transcription du gène ACC2 humain, comprenant le dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci.

7. Composition cosmétique destinée à traiter des états ou des troubles associés à la transcription du gène ACC2 humain, comprenant le dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci.

8. Composition pharmaceutique destinée à traiter le vieillissement de la peau, comprenant le dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci.

9. Composition cosmétique destinée à traiter le vieillissement de la peau, comprenant le dérivé d'acide nucléique peptidique selon la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci.

Fig. 1a



Fig. 1b



Fig. 1c



Fig. 2a

Examples of Non-substituted Alkyl Radical



Examples of Substituted Alkyl Radical



Fig. 2b

Examples of Non-substituted Alkylacyl Radical



Examples of Substituted Alkylacyl Radical



Examples of Substituted or Non-substituted Arylacyl Radical



Fig. 2c

Examples of Substituted Alkylamino or Arylamino Radical



Examples of Substituted or Non-substituted Aryl Radical



Examples of Substituted or Non-substituted Alkylsulfonyl or Arylsulfonyl Radical



Examples of Substituted or Non-substituted Alkyl- or Aryl-phosphonyl Radical



Fig. 2d

Examples of Substituted or Non-substituted Alkyloxycarbonyl Radical



Examples of Substituted or Non-substituted Aryloxycarbonyl Radical



Examples of Substituted or Non-substituted Alkylaminocarbonyl Radical



Examples of Substituted or Non-substituted Arylaminocarbonyl Radical



Fig. 2e

Examples of Substituted or Non-substituted Alkyloxythiocarbonyl Radical



Examples of Substituted or Non-substituted Alkylaminothiocarbonyl Radical



Examples of Substituted or Non-substituted Arylaminothiocarbonyl Radical



Examples of Substituted or Non-substituted Aryloxythiocarbonyl Radical



Fig. 3

PNA Monomer



B : Nucleobase
X : O (oxygen atom)
m : Integer
n : Integer

Adenine

B = 

Guanine

B = 

Thymine

B = 

Cytosine

B = 

Modified Cytosine

C(mXn) : B = 

Modified Adenine

A(m) : B = 

A(mXn) :

B = 

Modified Guanine

G(m) : B = 

G(mXn) :

B = 

Fig. 4



Fig. 5

Fmoc-PNA Monomer



B : Nucleobase with protecting group(s)
X : methylene, oxygen, sulfur, or Boc-protected amino
m : Integer
n : Integer

Boc- 

Modified Cytosine

C(mXn) : B = 

Modified Adenine

A(mXn) :

B = 

Modified Guanine

G(mXn) :

B = 

Fig. 6a


VWD1 A, Wavelength=260 nm (150317 2015-09-17 10-51-19\LB013-001-103_D)
mAU
120
100
80
60
40
20
0
min
5
10
15
20
25
30
35
40
45

Fig. 6b


VWD1 A, Wavelength=260 nm (2015\09\150923\150923 2015-09-23 17-33-39\LB013-001-136.D)
mAU
175
150
125
100
75
50
25
0
min
5
10
15
20
25
30
35
40
45

Fig. 7


+ESI Scan (0.038-0.278 min, 30 Scans) Frag=100.0V LB013-001-135.d Subtract Deconvoluted
x10 6
Counts vs. Mass-to-Charge (m/z)
4551.0846
4317.9453
2402.1198
1517.0270
921.0032
156.1624

Fig. 8


ASO 1
Con
1fM
1aM
0.1aM
Full Length
ΔExon11
Exon10
Exon12

Fig. 9


* p≤ 0.05, N= 2 per dose
ACC2 Rel. Expression
1.20
1.00
0.80
0.60
0.40
0.20
0.00
*
Con
100zM
1aM
1fM

Fig. 10


* p≤ 0.05, ** p≤ 0.01, N= 2 per dose
ACC2 Rel. Expression
1.20
1.00
0.80
0.60
0.40
0.20
0.00
*
**
Con
100zM
1aM
1fM

Fig. 11


* p≤ 0.05, N= 2 per dose
ACC2 Rel. Expression
1.20
1.00
0.80
0.60
0.40
0.20
0.00
*
*
Con
100zM
1aM
1fM

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- KR 2009001256 W **[0028] [0045] [0064]**
- EP 2268607 A **[0028]**
- US 8680253 B **[0028]**
- WO 2007110775 A **[0033]**
- WO 2018122610 A **[0033]**
- WO 2009113828 A **[0041] [0053]**
- US 6133444 A **[0064]**
- WO 9640685 A **[0064]**

Non-patent literature cited in the description

- *Recent Patents Cardiovasc. Drug Discov.,* 2007, vol. 2, 162-80 **[0006]**
- *PLoS One,* 2017, vol. 12, e0169566 **[0006] [0032]**
- *Science,* 2001, vol. 291, 2613-6 **[0007]**
- *Ann. Rev. Biochem.,* 2003, vol. 72 (1), 291-336 **[0010]**
- *Nature Rev. Mol. Cell Biol.,* 2005, vol. 6 (5), 386-398 **[0010]**
- *Nature Rev. Mol. Cell Biol.,* 2014, vol. 15 (2), 108-121 **[0010]**
- *Biochemistry,* 2002, vol. 41, 4503-4510 **[0012] [0022]**
- *Cancer Res.,* 1988, vol. 48, 2659-2668 **[0012]**
- *Clin. Exp. Pharmacol. Physiol.,* 2006, vol. 33, 533-540 **[0018] [0022]**
- *Ann. Rev. Biochem.,* 1985, vol. 54, 367-402 **[0019]**
- *Nucleic Acids Res.,* 1997, vol. 25, 3290-3296 **[0020]**
- *Circulation,* 2008, vol. 118 (7), 743-753 **[0023]**
- *Curr. Opin. Mol. Ther.,* 2004, vol. 6, 331-336 **[0023]**
- *Biochemistry,* 2006, vol. 45, 7347-7355 **[0024]**
- *Appl. Microbiol. Biotechnol.,* 2006, vol. 71, 575-586 **[0025]**
- *Science,* 1991, vol. 254, 1497-1500 **[0026]**
- *Nature (London),* 1992, vol. 365, 566-568 **[0026]**
- *Adv. Drug Delivery Rev.,* 2003, vol. 55, 267-280 **[0027]**
- *Microbiol. Mol. Biol. Rev.,* 2003, vol. 67 (4), 657-685 **[0031]**